[SCHEDULE 13G/A] Editas Medicine, Inc. Amended Passive Investment Disclosure
Rhea-AI Filing Summary
The Vanguard Group filed an amendment (Schedule 13G/A) reporting that it beneficially owns 0 shares of Editas Medicine common stock, representing 0% of the class. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership after internal reorganization.
The filing states The Vanguard Group beneficially owns 0 shares of Editas Medicine common stock and reports 0% ownership. The amendment cites an internal realignment on January 12, 2026
Cash‑flow treatment is not applicable; subsequent disclosures by Vanguard affiliates may show any separate beneficial positions. The current filing removes The Vanguard Group as an aggregated beneficial owner.
Amendment follows SEC Release No. 34-39538 disaggregation guidance.
The statement references reliance on SEC Release No. 34-39538 to report certain subsidiaries or business divisions separately after the January 12, 2026 realignment. It states those entities pursue the same investment strategies previously used.
This is an administrative ownership update; material investor impact depends on whether any affiliated entities report separate holdings in subsequent filings.